Table 3.
Association of PTEN polymorphisms with the risk of HCC
| SNP | Genotype/allele | Healthy controls | HBV natural clearance subjects | HBV- infected subjects without HCC | HBV- HCC patients | AOR (95% CI) | |||
|---|---|---|---|---|---|---|---|---|---|
| HBV-HCC patients versus healthy controls | HBV-HCC patients versus HBV clearance subjects | HBV-HCC patients versus HBV-infected subjects without HCC | HBV-HCC patients versus all of the controls | ||||||
| rs1234220 | TT | 816 | 235 | 770 | 766 | 1.00 | 1.00 | 1.00 | 1.00 |
| Total | CT | 181 | 61 | 184 | 233 | 1.37 (1.08–1.73) | 1.17 (0.82–1.67) | 1.28 (1.02–1.61) | 1.30 (1.08–1.56) |
| CC | 12 | 5 | 13 | 15 | 1.05 (0.48–2.33) | 0.73 (0.25–2.16) | 1.10 (0.50–2.41) | 1.12 (0.60–2.12) | |
| C (CT + CC) | 193 | 66 | 197 | 248 | 1.35 (1.07–1.69) | 1.13 (0.80–1.60) | 1.27 (1.01–1.57) | 1.29 (1.07–1.54) | |
| HWE P | 0.584 | ||||||||
| rs1234220 | TT | 199 | 106 | 240 | 124 | 1.00 | 1.00 | 1.00 | 1.00 |
| Females | CT | 46 | 24 | 61 | 36 | 1.46 (0.85–2.50) | 1.38 (0.76–2.53) | 1.20 (0.74–1.95) | 1.30 (0.85–1.98) |
| CC | 2 | 2 | 5 | 2 | 0.93 (0.13–6.87) | 0.75 (0.10–5.50) | 0.91 (0.17–5.01) | 0.92 (0.20–4.34) | |
| C (CT + CC) | 48 | 26 | 66 | 38 | 1.43 (0.84–2.41) | 1.33 (0.74–2.38) | 1.18 (0.74–1.90) | 1.27 (0.84–1.92) | |
| rs1234220 | TT | 617 | 129 | 530 | 642 | 1.00 | 1.00 | 1.00 | 1.00 |
| Males | CT | 135 | 37 | 123 | 197 | 1.35 (1.04–1.75) | 1.08 (0.70–1.66) | 1.31 (1.01–1.70) | 1.30 (1.06–1.60) |
| CC | 10 | 3 | 8 | 13 | 1.11 (0.46–2.65) | 0.74 (0.20–2.71) | 1.17 (0.47–2.88) | 1.20 (0.59–2.42) | |
| C (CT + CC) | 145 | 40 | 131 | 210 | 1.33 (1.03–1.71) | 1.05 (0.69–1.60) | 1.30 (1.01–1.67) | 1.29 (1.06–1.58) | |
| rs2299939 | GG | 624 | 188 | 587 | 660 | 1.00 | 1.00 | 1.00 | 1.00 |
| Total | GT | 337 | 96 | 358 | 306 | 0.91 (0.74–1.12) | 0.98 (0.72–1.34) | 0.75 (0.62–0.92) | 0.84 (0.71–0.99) |
| TT | 35 | 17 | 34 | 45 | 1.13 (0.69–1.83) | 0.82 (0.41–1.63) | 1.19 (0.74–1.92) | 1.10 (0.75–1.62) | |
| T (GT + TT) | 372 | 113 | 392 | 351 | 0.93 (0.77–1.13) | 0.96 (0.71–1.29) | 0.79 (0.65–0.96) | 0.86 (0.74–1.01) | |
| HWE P | 0.200 | ||||||||
| rs2299939 | GG | 142 | 85 | 187 | 102 | 1.00 | 1.00 | 1.00 | 1.00 |
| Females | GT | 92 | 41 | 111 | 55 | 0.86 (0.55–1.35) | 1.14 (0.68–1.89) | 0.87 (0.57–1.32) | 0.92 (0.64–1.33) |
| TT | 11 | 7 | 9 | 5 | 0.62 (0.20–1.95) | 0.75 (0.22–2.58) | 1.18 (0.37–3.72) | 0.75 (0.28–2.03) | |
| T (GT + TT) | 103 | 48 | 120 | 60 | 0.84 (0.54–1.29) | 1.09 (0.67–1.79) | 0.89 (0.59–1.34) | 0.90 (0.63–1.29) | |
| rs2299939 | GG | 482 | 103 | 400 | 558 | 1.00 | 1.00 | 1.00 | 1.00 |
| Males | GT | 245 | 55 | 247 | 251 | 0.93 (0.74–1.16) | 0.87 (0.59–1.30) | 0.72 (0.57–0.90) | 0.81 (0.68–0.98) |
| TT | 24 | 10 | 25 | 40 | 1.28 (0.74–2.23) | 0.78 (0.34–1.80) | 1.20 (0.71–2.02) | 1.18 (0.78–1.80) | |
| T (GT + TT) | 269 | 65 | 272 | 291 | 0.96 (0.77–1.20) | 0.86 (0.59–1.25) | 0.76 (0.62–0.95) | 0.85 (0.71–1.01) | |
| rs1234213 | CC | 248 | 71 | 237 | 253 | 1.00 | 1.00 | 1.00 | 1.00 |
| Total | CT | 518 | 158 | 494 | 486 | 0.94 (0.74–1.18) | 0.86 (0.60–1.23) | 0.93 (0.74–1.17) | 0.92 (0.76–1.10) |
| TT | 238 | 72 | 253 | 276 | 1.12 (0.86–1.46) | 1.12 (0.74–1.71) | 1.03 (0.80–1.34) | 1.08 (0.87–1.34) | |
| T (CT + TT) | 756 | 230 | 747 | 762 | 0.99 (0.80–1.23) | 0.94 (0.67–1.32) | 0.97 (0.78–1.20) | 0.97 (0.81–1.16) | |
| HWE P | 0.311 | ||||||||
| rs1234213 | CC | 61 | 33 | 81 | 34 | 1.00 | 1.00 | 1.00 | 1.00 |
| Females | CT | 123 | 65 | 146 | 77 | 1.22 (0.71–2.08) | 1.15 (0.63–2.10) | 1.32 (0.80–2.18) | 1.29 (0.82–2.02) |
| TT | 63 | 35 | 82 | 51 | 1.42 (0.78–2.57) | 1.35 (0.70–2.62) | 1.52 (0.88–2.63) | 1.49 (0.91–2.42) | |
| T (CT + TT) | 186 | 100 | 228 | 128 | 1.29 (0.78–2.13) | 1.24 (0.71–2.17) | 1.39 (0.87–2.23) | 1.37 (0.90–2.08) | |
| rs1234213 | CC | 187 | 38 | 156 | 219 | 1.00 | 1.00 | 1.00 | 1.00 |
| Males | CT | 395 | 93 | 348 | 409 | 0.89 (0.69–1.14) | 0.75 (0.48–1.18) | 0.85 (0.66–1.10) | 0.85 (0.69–1.05) |
| TT | 175 | 37 | 171 | 225 | 1.06 (0.79–1.42) | 1.04 (0.61–1.78) | 0.92 (0.69–1.24) | 1.00 (0.79–1.27) | |
| T (CT + TT) | 570 | 130 | 519 | 634 | 0.94 (0.74–1.20) | 0.83 (0.54–1.28) | 0.87 (0.68–1.11) | 0.90 (0.74–1.09) | |
AOR: Adjusted odds ratio (adjusted for age and gender); CI: Confidence interval; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HWE: Hardy-Weinberg equilibrium; PTEN: Phosphatase and tensin homolog; SNP: Single nucleotide polymorphism.